Synopsis
Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Carbidopa, (r)-isomer
2. Carbidopa, (s)-isomer
3. Lodosin
4. Lodosyn
5. Methyldopahydrazine
6. Mk 485
7. Mk 486
8. Mk-485
9. Mk-486
10. Mk485
11. Mk486
1. 28860-95-9
2. Lodosyn
3. Carbidopa Anhydrous
4. (s)-(-)-carbidopa
5. (s)-carbidopa
6. S-(-)-carbidopa
7. Alpha-methyldopahydrazine
8. L-alpha-methyldopahydrazine
9. N-aminomethyldopa
10. Carbidopum
11. Carbidopum [inn-latin]
12. Carbidopa (anhydrous)
13. S(-)-carbidopa
14. Mk 486
15. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid
16. Carbidopa [inn]
17. L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic Acid
18. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic Acid
19. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic Acid
20. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic Acid
21. Kr87b45rgh
22. (alphas)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic Acid
23. Chebi:39585
24. 28860-95-9 (anhydrous)
25. Ncgc00024596-05
26. Hadrazino-alpha-methyldopa
27. C-dopa
28. 3,3,3-trideuterio-2-[dideuterio-(3,4-dihydroxyphenyl)methyl]-2-hydrazinylpropanoic Acid
29. Smr000058235
30. Ccris 5093
31. Sr-01000597655
32. Einecs 249-271-9
33. Unii-kr87b45rgh
34. Benzenepropanoic Acid, .alpha.-hydrazino-3,4-dihydroxy-.alpha.-methyl-, (s)-
35. Alpha-hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic Acid
36. L-alpha-methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic Acid
37. L-alpha-methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic Acid
38. Mfcd00069231
39. Nd0611
40. Tocris-0455
41. C-126
42. Dsstox_cid_2735
43. Carbidopa [who-dd]
44. Dsstox_rid_76707
45. Dsstox_gsid_22735
46. Lopac0_000382
47. Schembl35084
48. Mls000069628
49. Mls002207014
50. S-(-)-carbidopa Monohydrate
51. Gtpl5159
52. Carbidopa, L- Anhydrous
53. Carbidopa Anhydrous [mi]
54. Chembl1201236
55. Dtxsid4022735
56. Hms2089b12
57. Hms3266a20
58. Hms3411m13
59. Hms3655g20
60. Hms3675m13
61. Hms3713l10
62. Hms3884m14
63. Hy-b0311
64. Tox21_110910
65. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methyl-propanoic Acid
66. Bdbm50418773
67. Nsc751137
68. S1891
69. Zinc19168887
70. Akos015969657
71. Benzenepropanoic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, (s)-
72. Hydrocinnamic Acid, Alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, L-
73. Ac-1676
74. Ccg-204476
75. Db00190
76. Sdccgmls-0072919.p025
77. Mls-0072919
78. Smp1_000057
79. Ncgc00024596-01
80. Ncgc00024596-03
81. Ncgc00024596-06
82. Ncgc00024596-07
83. Ncgc00024596-08
84. As-16862
85. Bc164279
86. Mls-0072919.p013
87. Cas-28860-95-9
88. Eu-0100382
89. Sw199080-2
90. 60c959
91. Ab00441332-05
92. Ab00441332-06
93. Ab00441332_07
94. Ab00441332_08
95. Sr-01000597655-1
96. Sr-01000597655-3
97. Sr-01000597655-5
98. Sr-01000597655-9
99. Brd-k78712176-001-07-5
100. Benzenepropanoic Acid, A-hydrazino-3,4-dihydroxy-a-methyl-
101. (-)-l-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinamic Acid
102. (s)-?-hydrazino-?-methyl-?-(3,4-dihydroxyphenyl)propionic Acid
103. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid
104. (s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoicacid
105. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic Acid
106. (2s)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropionic Acid Monohydrate
107. Benzenepropanoic Acid, .alpha.-hydrazinyl-3,4-dihydroxy-.alpha.-methyl-, (.alpha.s)-
108. Kinson; 3-(3,4-dihydroxy-phenyl)-2-hydrazino-2-methyl-propionic Acid
109. 1426847-87-1
Molecular Weight | 226.23 g/mol |
---|---|
Molecular Formula | C10H14N2O4 |
XLogP3 | -2.2 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 226.09535693 g/mol |
Monoisotopic Mass | 226.09535693 g/mol |
Topological Polar Surface Area | 116 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 261 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Carbidopa |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Amerigen Pharms |
2 of 4 | |
---|---|
Drug Name | Lodosyn |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Aton |
3 of 4 | |
---|---|
Drug Name | Carbidopa |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa and levodopa extended release tablets are extended release combination of carbidopa and levodopa for the treatment of Parkinsons disease and syndrome.Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Amerigen Pharms |
4 of 4 | |
---|---|
Drug Name | Lodosyn |
PubMed Health | Carbidopa (By mouth) |
Drug Classes | Antiparkinsonian |
Drug Label | Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as ()-L--hydrazino--methyl--(3,4-dihydroxybenzene) pro... |
Active Ingredient | Carbidopa |
Dosage Form | Tablet |
Route | Oral |
Strength | 25mg |
Market Status | Prescription |
Company | Aton |
Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication. The combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting. The product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage. As well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.
FDA Label
When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa]. The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot. Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Aromatic Amino Acid Decarboxylase Inhibitors
Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism. (See all compounds classified as Aromatic Amino Acid Decarboxylase Inhibitors.)
Dopamine Agents
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)
Absorption
When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed. Once absorbed, carbidopa shows bioavailability of 58%. A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.
Route of Elimination
In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.
Volume of Distribution
The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg. However, carbidopa is widely distributed in the tissues, except in the brain. After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.
Clearance
The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.
The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).
The reported half-life of carbidopa is of approximately 107 minutes.
Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa. DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine. DDC can be found in the body periphery and in the blood-brain barrier. The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier. Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
64
PharmaCompass offers a list of Carbidopa API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Carbidopa manufacturer or Carbidopa supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carbidopa manufacturer or Carbidopa supplier.
PharmaCompass also assists you with knowing the Carbidopa API Price utilized in the formulation of products. Carbidopa API Price is not always fixed or binding as the Carbidopa Price is obtained through a variety of data sources. The Carbidopa Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid, including repackagers and relabelers. The FDA regulates alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid supplier is an individual or a company that provides alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid active pharmaceutical ingredient (API) or alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid finished formulations upon request. The alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers may include alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid API manufacturers, exporters, distributors and traders.
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid DMF (Drug Master File) is a document detailing the whole manufacturing process of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid active pharmaceutical ingredient (API) in detail. Different forms of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid DMFs exist exist since differing nations have different regulations, such as alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid DMF submitted to regulatory agencies in the US is known as a USDMF. alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid USDMF includes data on alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid Drug Master File in Japan (alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid JDMF) empowers alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid JDMF during the approval evaluation for pharmaceutical products. At the time of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid Drug Master File in Korea (alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid. The MFDS reviews the alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid KDMF as part of the drug registration process and uses the information provided in the alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid KDMF to evaluate the safety and efficacy of the drug.
After submitting a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid API can apply through the Korea Drug Master File (KDMF).
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers with KDMF on PharmaCompass.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEP of the European Pharmacopoeia monograph is often referred to as a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid Certificate of Suitability (COS). The purpose of a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid to their clients by showing that a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEP has been issued for it. The manufacturer submits a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEP (COS) as part of the market authorization procedure, and it takes on the role of a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEP holder for the record. Additionally, the data presented in the alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid DMF.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers with CEP (COS) on PharmaCompass.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid written confirmation (alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid WC) is an official document issued by a regulatory agency to a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid manufacturer, verifying that the manufacturing facility of a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid APIs or alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid finished pharmaceutical products to another nation, regulatory agencies frequently require a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid WC (written confirmation) as part of the regulatory process.
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid suppliers with NDC on PharmaCompass.
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid GMP manufacturer or alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid GMP API supplier for your needs.
A alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CoA (Certificate of Analysis) is a formal document that attests to alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid's compliance with alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid specifications and serves as a tool for batch-level quality control.
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CoA mostly includes findings from lab analyses of a specific batch. For each alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid may be tested according to a variety of international standards, such as European Pharmacopoeia (alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid EP), alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid USP).